My Recent Searches
- No Recent Search.
My Tests Viewed
- No Test Viewed.
NPM (Exon 12) Mutation Analysis, Cell-based
Acute Myeloid Leukemia (AML) is a clinically heterogeneous disease. Recurrent cytogenetic abnormalities help define subgroups with different prognosis and identify patients whom might benefit from targeted therapies. However, almost half adults AML cases display a normal karyotype by conventional cytogenetics, and the clinical and molecular features of this large subgroup of patients are poorly understood. The NPM exon 12 mutation can serve as predictor in AML cases with a normal karyotype, good response to induction chemotherapy and as a marker for monitoring of minimal residual disease. NPM exon 12 mutations are AML-specific since they are not detected in normal cells or other neoplasms.
Nucleophosmin,Acute Myeloid Leukemia (AML)
To view specimen requirements and codes please Select a regional laboratory.
Not sure which laboratory serves your office? Call us 866-MYQUEST (866-697-8378)
Reference ranges are provided as general guidance only. To interpret test results use the reference range in the laboratory report.
(The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.)
* The tests listed by specialist are a select group of tests offered. For a complete list of Quest Diagnostics tests, please refer to our Directory of Services.